 <h1>Libtayo Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>cemiplimab</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about cemiplimab. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Libtayo.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cemiplimab: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, cemiplimab (the active ingredient contained in Libtayo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking cemiplimab:</p><p>
<i>More common</i>
</p><ul>
<li>Chills</li>
<li>cough</li>
<li>diarrhea</li>
<li>fever</li>
<li>hoarseness</li>
<li>itching, skin rash</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bladder pain</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>chest pain or discomfort</li>
<li>confusion</li>
<li>dark urine</li>
<li>dizziness</li>
<li>fainting</li>
<li>frequent urge to urinate</li>
<li>general feeling of discomfort or illness</li>
<li>general tiredness and weakness</li>
<li>headache</li>
<li>light-colored stools</li>
<li>lightheadedness</li>
<li>muscle or bone pain</li>
<li>muscle weakness</li>
<li>nausea</li>
<li>nervousness</li>
<li>pain, redness, swelling, tenderness, or warmth on the skin</li>
<li>pale skin</li>
<li>pounding in the ears</li>
<li>rapid, shallow breathing</li>
<li>slow or fast heartbeat</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stiff neck or back</li>
<li>thickening of bronchial secretions</li>
<li>tightness in the chest</li>
<li>trouble breathing</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>upper right abdominal pain</li>
<li>vomiting</li>
<li>yellow eyes and skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of cemiplimab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Constipation</li>
<li>decreased appetite</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cemiplimab: intravenous solution</i></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Uveitis, iritis, retinal detachment, visual impairment, blindness<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Myocarditis, pericarditis, vasculitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (e.g., maculopapular rash, dermatitis, generalized rash, dermatitis bullous, drug eruption, erythema, erythematous rash, macular rash, pruritic rash, skin reaction) (25%), pruritus (15%)<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Hypothyroidism, hyperthyroidism</p>
<p><b>Uncommon</b> (0.1% to 1%): Adrenal insufficiency, hypophysitis, thyroiditis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea/colitis (22%), nausea (19%), constipation (12%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Colitis, pancreatitis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Immunogenicity</p>
<p><b>Uncommon</b> (0.1% to 1%): Sjogren's syndrome, immune thrombocytopenic purpura<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Infusion-related reactions<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (10%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Type 1 diabetes mellitus, myositis, rhabdomyolysis, arthritis, polymyalgia rheumatica<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (e.g., back pain, myalgia, neck pain, pain in extremity (17%)</p>
<p>Common (1% to 10%: Arthralgia, arthritis, muscular weakness<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis, Guillain-Barre syndrome, nerve paresis, autoimmune neuropathy, central nervous system inflammation, neuropathy peripheral, chronic inflammatory demyelinating polyradiculoneuropathy, Myasthenia gravis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia (29%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Hepatitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Nephritis, renal failure<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Libtayo (cemiplimab)." Regeneron Pharmaceuticals Inc, Tarrytown, NY. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What type of drug is Libtayo?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Libtayo (cemiplimab)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>2 Reviews</li>
<li>Drug class: anti-PD-1 monoclonal antibodies</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Libtayo &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Squamous Cell Carcinoma</li>
<li>Basal Cell Carcinoma</li>
<li>Non-Small Cell Lung Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cemiplimab: intravenous solution</i></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Uveitis, iritis, retinal detachment, visual impairment, blindness<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Myocarditis, pericarditis, vasculitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (e.g., maculopapular rash, dermatitis, generalized rash, dermatitis bullous, drug eruption, erythema, erythematous rash, macular rash, pruritic rash, skin reaction) (25%), pruritus (15%)<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Hypothyroidism, hyperthyroidism</p><p><b>Uncommon</b> (0.1% to 1%): Adrenal insufficiency, hypophysitis, thyroiditis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea/colitis (22%), nausea (19%), constipation (12%)</p><p><b>Uncommon</b> (0.1% to 1%): Colitis, pancreatitis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Immunogenicity</p><p><b>Uncommon</b> (0.1% to 1%): Sjogren's syndrome, immune thrombocytopenic purpura<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Infusion-related reactions<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (10%)</p><p><b>Uncommon</b> (0.1% to 1%): Type 1 diabetes mellitus, myositis, rhabdomyolysis, arthritis, polymyalgia rheumatica<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (e.g., back pain, myalgia, neck pain, pain in extremity (17%)</p><p>Common (1% to 10%: Arthralgia, arthritis, muscular weakness<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis, Guillain-Barre syndrome, nerve paresis, autoimmune neuropathy, central nervous system inflammation, neuropathy peripheral, chronic inflammatory demyelinating polyradiculoneuropathy, Myasthenia gravis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia (29%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Hepatitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Nephritis, renal failure<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Libtayo (cemiplimab)." Regeneron Pharmaceuticals Inc, Tarrytown, NY. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What type of drug is Libtayo?</li>
</ul><h2>More about Libtayo (cemiplimab)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>2 Reviews</li>
<li>Drug class: anti-PD-1 monoclonal antibodies</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Libtayo &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Squamous Cell Carcinoma</li>
<li>Basal Cell Carcinoma</li>
<li>Non-Small Cell Lung Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>